LELYSTAD, The Netherlands, February 8, 2012 /PRNewswire/ --
Pepscan Therapeutics B.V., the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has achieved two milestones in the Research Collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments.
In the collaboration, Pepscan has discovered novel peptides with potential therapeutic utility using its proprietary peptide array platform for high throughput synthesis and screening of conformationally stabilized CLIPS peptides.
“The achievement of these milestones demonstrates the effectiveness of our high throughput peptide array technology for the discovery of novel peptides with excellent activity and proteolytic stability,” said Wim Mol, CEO of Pepscan. “We consider this achievement a further expression of our expertise in the field of peptide lead discovery and optimization.”
About Pepscan
Pepscan Therapeutics B.V. is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.
About CLIPS
CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have been shown to exert excellent activity and stability. CLIPS peptides are also used as superior immunogens for antibody generation against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs.
SOURCE Pepscan Therapeutics B.V.
